Search

Carol Morris, MD, MS, has assumed the position of Chief of the Orthopaedic Surgery Service at Memorial Sloan Kettering Cancer Center (MSK).

… Friday, October 14, 2022 Carol Morris, MD, MS, has assumed the position of Chief of the Orthopaedic Surgery Service at Memorial Sloan Kettering Cancer Center (MSK). A skilled surgeon and talented leader, Dr. Morris has a deep familiarity with MSK, having previously spent 14 years at the institution as

Memorial Sloan Kettering researchers helped to identify a key insight into what first goes wrong in the development of many leukemias.

… Thursday, June 30, 2011 Researchers at Memorial Sloan Kettering Cancer Center and New York University have discovered how a mutation in the gene known as TET2 contributes to the development of some leukemias . When a mutation in TET2 occurs, it enhances the function of blood stem cells in the bone marrow

Learn about Jakki Stout’s journey from MSK nurse practitioner to breast cancer patient and back to being an even more helpful and inspiring nurse at MSK.

… Monday, June 10, 2024 It’s easy to see that nurse practitioner Jaclyn Stout has a true passion for nursing. Jakki, as she’s called, is a skilled and compassionate caregiver who’s been at Memorial Sloan Kettering Cancer Center (MSK) for 10 years. She loves her work caring for surgery patients recovering

Risk-reducing salpingo-oophorectomy brings on early menopause and its attendant consequences. Researchers are exploring whether a less drastic surgical strategy can offer a safe and efficacious option.

… Friday, September 16, 2016 Since there is no effective screening test for ovarian cancer , the gold standard management approach for women who are at an increased risk for developing ovarian cancer is a risk-reducing salpingo-oophorectomy (RRSO), a surgical procedure to remove ovaries and fallopian tubes

Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials.

… Friday, September 21, 2018 Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials. The task force was announced in a statement from MSK President and

Learn how experimental vaccine might train the immune system to prevent pancreatic cancer from returning.

… Monday, June 10, 2024 Pancreatic cancer has long been a forbidding disease. While the five-year survival rate has inched upward in recent years, it remains quite low — about 12%. But surgeon-scientist Vinod Balachandran, MD , has focused on a glimmer of hope: A small percentage of people manage to beat

Discover what Memorial Sloan Kettering contributed to the science and medicine of x-rays.

… Tuesday, October 4, 2016 Summary Since 1902, Memorial Sloan Kettering has been a pioneer in the science and medicine of x-rays, developing many of the radiation techniques in use today. In a previous post , we recounted the history of radium therapy at Memorial Sloan Kettering. Radium, a naturally occurring

Investigators at Memorial Sloan Kettering Cancer Center, along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large-scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.

… Monday, July 27, 2009 Investigators at Memorial Sloan Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the

Learn about insights that could lead to a new class of drugs against cancers caused by RAS gene mutations.

… Wednesday, October 30, 2024 Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS , and HRAS . RAS-family mutations are associated with numerous types of cancer. KRAS mutations are found in pancreatic cancer ,  colorectal cancer , 

Clues emerge about why promising new breast cancer drugs sometimes don’t work — and what might be done about it.

… Monday, December 10, 2018 Summary A new class of drugs called CDK4/6 inhibitors has been effective in women with breast cancer . However, some people don’t respond to the drugs, or they develop resistance over time. A study by MSK researchers has identified two genes linked to this resistance. The most